Welcome to our dedicated page for Lantern Pharma SEC filings (Ticker: LTRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lantern Pharma Inc. (NASDAQ: LTRN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as an AI-driven, clinical-stage oncology and pharmaceutical preparation manufacturing issuer. Through documents filed with the U.S. Securities and Exchange Commission, investors can review how Lantern reports its financial condition, governance decisions, and material events related to its RADR® AI platform and oncology drug pipeline.
Lantern files annual reports on Form 10-K and quarterly reports on Form 10-Q that describe its business model, risk factors, clinical programs such as LP-184, LP-284, and LP-300, and the role of its RADR® artificial intelligence and machine learning platform in oncology drug discovery and development. Current reports on Form 8-K disclose specific material events, including quarterly financial results, at-the-market equity offering agreements, changes to bylaws, board appointments, and outcomes of annual stockholder meetings, such as director elections and equity incentive plan matters.
Proxy materials, including definitive proxy statements on Schedule 14A, outline Lantern’s corporate governance structure, proposals submitted to stockholders, and details on topics like the repricing of stock options under its equity incentive plan or the ratification of independent auditors. These filings help investors understand how Lantern’s board and management approach capital structure, executive compensation, and shareholder rights as the company advances its AI-enabled oncology strategy.
On Stock Titan, Lantern’s SEC filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify discussion of the RADR® platform, clinical trial progress, regulatory designations, and financing arrangements. Users can monitor real-time updates from EDGAR, review historical filings for context on LTRN’s evolution, and examine governance and compensation disclosures alongside clinical and platform milestones. This page is a central reference for anyone analyzing Lantern Pharma’s regulatory record, from long-form 10-K narratives to focused 8-K announcements.
Lantern Pharma Inc. reported that Thomas A. Satterfield, Jr. beneficially owns 570,000 shares of Common Stock, representing 5.1% of the class. The filing breaks the position into 95,000 shares with sole voting/dispositive power and 475,000 shares with shared voting/dispositive power, and cites 11,254,697 shares outstanding as of March 13, 2026.
The filing lists specific holder vehicles: 45,000 shares held by Tomsat Investment & Trading Co., Inc.; 250,000 by Caldwell Mill Opportunity Fund, LLC; 150,000 by A.G. Family L.P.; and 30,000 by Satterfield Vintage Investments, L.P. Ownership links and control relationships are described in the filing.
Lantern Pharma Inc. filed a preliminary prospectus supplement to offer shares of its common stock in a best-efforts placement led by ThinkEquity LLC. The supplement discloses that there is no minimum offering amount, placement agent fees and placement agent warrants equal to 3% of shares sold, and that proceeds will be used for working capital and general corporate purposes.
The company reports a public float of $35,164,013 based on 11,208,938 shares, 11,254,687 shares outstanding as of December 31, 2025, total assets of approximately $11.04M, and working capital of approximately $6.5M. The filing notes ongoing clinical programs for LP-300, LP-184 and LP-284 and planned FDA Type C meeting for proposed HARMONIC study amendments.
Lantern Pharma Inc. files its annual report describing an AI-driven oncology business that remains pre-revenue and faces substantial doubt about its ability to continue as a going concern without significant new funding. The company relies on its RADR® platform, which analyzes over 200 billion oncology-focused data points and 130,000 patient records, to select and develop drug candidates.
Lantern’s pipeline includes three clinical-stage small molecules—LP-300 for never-smoker non-small cell lung cancer, LP-184 for multiple solid tumors and CNS cancers, and LP-284 for hematologic malignancies—plus an antibody-drug conjugate program. LP-184 has received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations in several indications, and two Phase 1b/2 INDs were cleared in 2025.
The LP-300 Phase 2 HARMONIC™ trial targets never-smoker NSCLC patients who relapsed after tyrosine kinase inhibitors, building on prior subgroup data where female patients on LP-300 plus paclitaxel/cisplatin showed median overall survival of 25.0 months versus 13.2 months on chemotherapy alone. Lantern is also preparing to commercialize its RADR® and withZeta.ai AI platforms via subscriptions and services starting in 2026.
Lantern Pharma Inc. reported narrower losses for 2025 while advancing its AI-driven oncology pipeline and platforms. Full-year net loss was about $17.1 million (or $1.57 per share), improving from roughly $20.8 million (or $1.93 per share) in 2024.
Research and development expenses fell to approximately $11.5 million, down 29%, while general and administrative costs rose modestly to about $6.5 million. Cash, cash equivalents and marketable securities were around $10.1 million as of December 31, 2025, and the company expects this to fund operations only until roughly late July to mid September 2026, so it is actively pursuing additional financing. During 2025 and early 2026 Lantern advanced multiple clinical programs, expanded its RADR® AI platform, launched the withZeta.ai co-scientist platform, and confirmed its CEO remains in place after refuting an online resignation rumor.
Lantern Pharma Inc. received an updated ownership filing showing a Bios-affiliated investment group holding a significant minority stake. Bios Capital Management, Bios Advisors GP, Cavu entities, several Bios funds and individuals Leslie W. Kreis and Aaron G.L. Fletcher may be deemed to beneficially own 960,026 common shares, representing 8.58% of the outstanding stock, all with shared voting and dispositive power and no sole voting authority. The percentages are based on 11,184,423 shares outstanding as disclosed in Lantern Pharma’s Form 10‑Q filed on November 5, 2025. This Amendment No. 5 updates prior ownership statements without describing new transactions in this excerpt.
Lantern Pharma Inc. filed a current report describing an investor and stakeholder event held on January 22, 2026. During this event, the company used a presentation to support discussions and a live demonstration of its initial artificial intelligence tools and multi-agent system that are being developed to focus on rare cancers. The same presentation is furnished as Exhibit 99.1 to the report and is not treated as formally filed financial information. This update is intended to share information under Regulation FD, giving the market equal access to the materials used at the event.
Lantern Pharma Inc. reported that director D. Jeffrey Keyser received two grants of stock options in the company. On January 9, 2026, he was awarded a stock option to buy 25,000 shares of common stock at an exercise price of $3.49 per share and a second stock option to buy 28,844 shares of common stock at the same $3.49 exercise price.
The first option for 25,000 shares will vest in equal monthly installments over 24 months starting February 9, 2026. The second option for 28,844 shares will vest in equal monthly installments over 12 months starting February 9, 2026. Both grants were made under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan, and the filing shows these option holdings as directly owned by the reporting person.
Lantern Pharma Inc. director Maria-Luisa Maccecchini reported receiving two stock option grants. On January 9, 2026, she was awarded a stock option to buy 25,000 shares of common stock at an exercise price of $3.49 per share, with the option priced at $0.00 on the grant date. She also received a second stock option for 21,152 shares at the same $3.49 exercise price.
Both grants were made under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The 25,000-share option vests in equal monthly installments over 24 months starting February 9, 2026, while the 21,152-share option vests in equal monthly installments over 12 months beginning on the same date. Following these grants, she directly beneficially owns 25,000 and 21,152 derivative securities, respectively.
Lantern Pharma Inc. director Chandru Vijay reported receiving two new stock option grants. On January 9, 2026, he was granted stock options to buy 25,000 shares of common stock at an exercise price of $3.49 per share under the company’s Amended and Restated 2018 Stock Incentive Plan. These options vest in equal monthly installments over 24 months starting February 9, 2026.
On the same date, he also received stock options to buy an additional 17,307 shares of common stock at an exercise price of $3.49 per share under the same plan. This second grant vests in equal monthly installments over 12 months beginning February 9, 2026. Both grants are reported as directly owned derivative securities.
Lantern Pharma director Lee Troy Schalop reported new equity awards on a Form 4. On January 9, 2026, he received two grants of stock options (rights to buy common stock) with an exercise price of $3.49 per share. One grant covers 25,000 options that vest in equal monthly installments over 24 months starting February 9, 2026. The second grant covers 18,460 options that vest in equal monthly installments over 12 months starting the same date. Both awards were reported at a transaction price of $0.00 per option, reflecting that these are option grants rather than open-market purchases or sales.